
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc. is positioned for significant growth due to multiple anticipated catalysts, which could potentially lead to a substantial increase in stock value. The company's focus on actionable mutations, with drugs like silevertinib demonstrating strong clinical efficacy—including a 60% confirmed overall response rate—supports a favorable outlook for market opportunities, particularly in the lucrative first-line non-small cell lung cancer (NSCLC) segment. Additionally, expected forecasted sales of approximately $500-750 million for their pipeline therapies, compared to the M&A valuations of similar-sized oncology firms, suggests a compelling upside potential for investors.
Bears say
The analysis of Black Diamond Therapeutics Inc reveals concerns regarding the effectiveness and competitive positioning of its drug candidates, particularly silevertinib, which has exhibited lower objective response rates (ORR) compared to competitors in similar clinical settings. The company’s reliance on a lower dosage has raised doubts about the replicability of its reported 60% ORR and overall confidence in its pipeline, leading to a lack of investor confidence reflected in its market capitalization of approximately $230 million. Additionally, the risk associated with varying patient populations and mutation types in ongoing trials may further limit the therapeutic potential and market traction of silevertinib, creating an unfavorable outlook for the company’s stock performance.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares